MONCYTE Health has been selected to participate in AMPlify, the U.S. market entry program delivered through the collaboration between Mayo Clinic and Business Finland. The highly competitive program supports a select group of Finnish HealthTech companies with strong international growth potential by providing access to world-class clinical expertise, market insights, and strategic networks within the U.S. healthcare ecosystem.
Participation in AMPlify represents an important milestone in MONCYTE Health’s international growth strategy and reinforces the company’s commitment to bringing innovative cardiovascular diagnostics to global healthcare markets.
The U.S. healthcare market offers significant opportunities for novel technologies that improve disease understanding, patient stratification, and treatment monitoring. Through AMPlify, MONCYTE Health will work alongside leading experts from Mayo Clinic and Business Finland to refine its market strategy, strengthen commercial readiness, and establish meaningful collaborations with key stakeholders across the healthcare and life sciences sectors.
MONCYTE Health has developed a proprietary blood-based technology that provides real-time cellular insights into human metabolism and immune function. By analyzing living blood cells, the platform delivers clinically relevant information that supports a deeper understanding of cardiovascular disease mechanisms, residual cardiovascular risk, chronic inflammation, and individual responses to therapeutic interventions.
The technology has broad potential applications across clinical care, biomedical research, and pharmaceutical development. By enabling more precise assessment of disease activity and treatment effects, MONCYTE Health aims to support the transition toward more personalized and preventive cardiovascular care.
“We are honored to be selected for the AMPlify program and to have the opportunity to engage with the expertise and network of Mayo Clinic and Business Finland,” said Simon Pfisterer, Chief Scientific Officer and founder of MONCYTE Health. “The program provides an exceptional platform to accelerate our U.S. market strategy, validate our value proposition with leading healthcare experts, and build partnerships that support our long-term mission of improving cardiovascular health through innovative cellular diagnostics.”
The AMPlify program is designed to help Finnish health technology companies navigate the complexities of entering the U.S. market by combining mentorship, clinical expertise, commercialization support, and access to one of the world’s leading healthcare organizations. Participation reflects both the scientific quality of the selected companies and their potential to create meaningful impact within global healthcare.
MONCYTE Health looks forward to collaborating with fellow innovators, clinical experts, and industry partners throughout the program as the company continues to advance precision diagnostics and expand its international presence.